Get started
Author

Kerstin Folkerts

Observed names: Folkerts, K., Folkerts, Kerstin, K Folkerts, K. Folkerts
Institution: Bayer (Germany)
OpenAlex ID: A5091535172
Adherence to Chronic Kidney Disease Screening Guidelines Among Patients With Type 2 Diabetes in a US Administrative Claims Database
2021 · Kerstin Folkerts, Natalia Petruski-Ivleva, et al. · Mayo Clinic Proceedings · 58
Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database
2020 · Kerstin Folkerts, Natalia Petruski-Ivleva, et al. · Journal of Managed Care & Specialty Pharmacy · 57
PDF
Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show underutilisation of preventive therapies
2011 · Sharon Welner, Maria Kubin, et al. · Thrombosis and Haemostasis · 43
High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database
2022 · Linda Fried, Niklas Schmedt, et al. · Nephrology Dialysis Transplantation · 41
PDF
Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape
2024 · Nihar Desai, Elzbieta Olewinska, et al. · Heart Failure Reviews · 36
PDF
Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain
2013 · Manuel Monreal, Kerstin Folkerts, et al. · Thrombosis and Haemostasis · 26
Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors
2022 · Csaba Kovesdy, Niklas Schmedt, et al. · BMC Medicine · 24
PDF
Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study
2020 · Csaba P Kovesdy, Danielle Isaman, et al. · Clinical Kidney Journal · 24
PDF
Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism – The COSIMO study
2021 · Alexander T. Cohen, Anthony Maraveyas, et al. · Thrombosis Research · 23
PDF
The Burden of Major Adverse Cardiac Events and Antiplatelet Prevention in Patients with Coronary or Peripheral Arterial Disease
2015 · Hanane Khoury, Louis Lavoie, et al. · Cardiovascular Therapeutics · 23
Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review
2018 · Jean-Baptiste Briere, Kevin Bowrin, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 22
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective
2012 · Heather McDonald, Alex Diamantopoulos, et al. · Journal of Medical Economics · 21
PDF
Risk of recurrent venous thromboembolism after discontinuation of vitamin K antagonist treatment: a nested case–control study
2016 · C. Martinez, A. Katholing, et al. · Journal of Thrombosis and Haemostasis · 18
ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease
2021 · Linda F. Fried, MD, MPH;Petruski-Ivleva,Natalia;Kerstin Folkerts, MSc;Niklas Schmedt, DrPH;Velentgas,Priscilla;Csaba P. Kovesdy, MD;, Natalia Petruski-Ivleva, et al. · The American Journal of Managed Care · 11
Cardiovascular and Renal Outcomes in Patients with Type-2 Diabetes and Chronic Kidney Disease Identified in a United States Administrative Claims Database: A Population Cohort Study
2021 · Kerstin Folkerts, Amanda M.B. Kelly, et al. · The Nephron journals/Nephron journals · 11
Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes
2023 · Peter Rossing, Franziska Groehl, et al. · Journal of Medical Economics · 10
PDF
Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease
2022 · Kerstin Folkerts, Aurelie Millier, et al. · Journal of Nephrology · 8
PDF
Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England & Wales: results of the FINE-CKD model
2025 · David Cherney, Aleksandra Drzewiecka, et al. · Journal of Medical Economics · 7
Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK
2019 · Kerstin Folkerts, Julie Broughton, et al. · Journal of Medical Economics · 6
PDF
Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis
2018 · Stefan Cano, Lorenzo Mantovani, et al. · TH Open · 6
PDF
Steroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS)
2025 · Emma Richard, Judith Stephenson, et al. · Pragmatic and Observational Research · 3
Treatment Patterns, Adverse Events, and Clinical Outcomes with Steroidal Mineralocorticoid Receptor Antagonists: A Retrospective Analysis of Administrative Claims Data (RELICS)
2025 · Emma Richard, Nihar Desai, et al. · Pragmatic and Observational Research · 3
PDF
FC083: Finerenone and Canagliflozin in the Treatment of Chronic Kidney Disease and Type 2 Diabetes: Matching-Adjusted Indirect Treatment Comparison of Fidelio-DKD and Credence
2022 · David Cherney, Kerstin Folkerts, et al. · Nephrology Dialysis Transplantation · 3
Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer
2019 · A.T. Cohen, A. Maraveyas, et al. · Annals of Oncology · 3
PDF
Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis
2018 · Lorenzo G. Mantovani, Sylvia Haas, et al. · European Journal of Internal Medicine · 3
PDF
Works count: 51
Citation count: 500
H-index: 13
I10-index: 16
Year
Topic
Type